Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Early Biotransformations of Oxaliplatin after Its Intravenous Administration to Cancer Patients

Pierre Allain, Oliver Heudi, Annie Cailleux, Anne Le Bouil, Francis Larra, Michele Boisdron-Celle and Erik Gamelin
Drug Metabolism and Disposition November 2000, 28 (11) 1379-1384;
Pierre Allain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Heudi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annie Cailleux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Le Bouil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis Larra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Boisdron-Celle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Gamelin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This article deals with the fate of oxaliplatin 1 and 3 h after its i.v. administration (130 mg/m2) to three patients. Its binding to plasma proteins and penetration into red blood cells were monitored by chromatography on-line with inductively coupled plasma mass spectrometry. Oxaliplatin biotransformations in plasma ultrafiltrate (PUF) and in urine were studied by chromatography coupled to inductively coupled plasma mass spectrometry or to electrospray ionization mass spectrometry. In plasma, four platinum (Pt) compounds were found. The peaks at 200 and 160 kDa corresponding to γ-globulins contained 40% of the Pt bound; the peak at 60 kDa corresponding to albumin contained 40% of the Pt found. The peak <2 kDa could correspond to oxaliplatin, to its degradation products, or to adducts between Pt compounds and low-molecular-weight species such as glutathione, l-methionine, andl-cysteine. In PUF and urine, oxaliplatin itself, its degradation products, Pt(dach)Cl2, [Pt(dach)(OH2)Cl]+, and species that have the same retention times as Pt(dach)(methionine) and [Pt(dach)]2(glutathione) were found. One hour after infusion, oxaliplatin in PUF and urine represented 12 and 50% of the total Pt, respectively. Three hours after infusion, oxaliplatin, undetectable in PUF, represented 10% of total Pt in urine. Inside red blood cells, two Pt compounds were found. The Pt peak at 60 kDa corresponding to hemoglobin and the peak <2 kDa corresponding to low-molecular species contained, respectively, 60% and 40% of Pt found. This study demonstrates that in the first hours after its infusion, oxaliplatin, in addition to other Pt compounds, is present in plasma and urine and that Pt is bound to albumin, γ-globulins, and hemoglobin.

Footnotes

  • Send reprint requests to: Professor Pierre Allain, Laboratoire de Pharmacologie et Toxicologie, Centre Hospitalier Universitaire, 49033 Angers CEDEX 01 France. E-mail:PharmacoToxico{at}chu-angers.fr

  • This work was performed while one of us (O.H.) was a recipient of a grant from “la Ligue Nationale contre le Cancer”.

  • Abbreviations used are::
    Pt
    platinum
    OP
    oxaliplatin
    RBC
    red blood cell
    PUF
    plasma ultrafiltrate
    RPLC
    reversed phase liquid chromatography
    ICPMS
    inductively coupled plasma mass spectrometry
    LC-MS
    electrospray ionization mass spectrometry
    5-FU
    5-fluorouracil
    DP
    Pt(dach)Cl2
    MP
    [Pt(dach)(OH2)Cl]+
    • Received February 15, 2000.
    • Accepted July 28, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (11)
Drug Metabolism and Disposition
Vol. 28, Issue 11
1 Nov 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Early Biotransformations of Oxaliplatin after Its Intravenous Administration to Cancer Patients
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Early Biotransformations of Oxaliplatin after Its Intravenous Administration to Cancer Patients

Pierre Allain, Oliver Heudi, Annie Cailleux, Anne Le Bouil, Francis Larra, Michele Boisdron-Celle and Erik Gamelin
Drug Metabolism and Disposition November 1, 2000, 28 (11) 1379-1384;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Early Biotransformations of Oxaliplatin after Its Intravenous Administration to Cancer Patients

Pierre Allain, Oliver Heudi, Annie Cailleux, Anne Le Bouil, Francis Larra, Michele Boisdron-Celle and Erik Gamelin
Drug Metabolism and Disposition November 1, 2000, 28 (11) 1379-1384;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Humanized PXR-CAR-CYP3A4/7 Mouse as Model of Induction
  • Ozanimod Human Metabolism and Disposition
  • Clearance Pathways: Fevipiprant with Probenecid Perpetrator
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics